Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative: early-phase trial registry
5 of 7 indexed B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 5 currently recruiting · #2,497 of 28,707 conditions by registered trial count
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative: 7 US clinical trials tracked, 5 recruiting.
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition b-acute-lymphoblastic-leukemia-philadelphia-chromosome-negative
OPEN 5 | RECR 71% | LATE 1 | EARLY 6 | RANK #2497 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Endometrial Carcinoma (71% recruiting · 7 trials)
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative lists 5 open slots (71% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative is recruiting above its size-band peers.
5 of 7 indexed trials (71.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative research.
National Cancer Institute (NCI) accounts for 3 of 7 trials (42.9%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative trials plan to enrol fewer than 100 people.
Median target enrolment is 53 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.
-
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT01371630
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT03739814
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
City of Hope Medical Center
NCT06918431
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
University of Washington
NCT05453500
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
University of Washington
NCT06738368
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT02003222
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT02484430
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative page
7 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative condition card totals 7 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.